Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Nov 2011

de Castro-Carpeño J, Perona R, Belda-Iniesta C

Abstract excerpt

The discovery of anaplastic lymphoma kinase (ALK) rearrangements in a subset of patients with nonsmall- cell lung cancer (NSCLC) and its potential blockage by specific inhibitors such as crizotinib has been one of the latest advances in the treatment of this disease. In this article, we will review the most important clinical aspects of ALK alterations in NSCLC patients and the pending questions to answer: the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Crizotinib

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 22082640
DOI: 10.1007/s12094-011-0732-8

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.PMID 22082640Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Semantic proximity Read ↗

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Semantic proximity Read ↗

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.Semantic proximity Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.